Tezspire nearly eliminated the need for surgery, reducing surgical intervention by 98 per cent
The goal is to deliver greater value to customers, doctors, and the broader healthcare ecosystem
This predictive technology empowers people with diabetes to take preventive action before complications arise
The Phase Ib MAD study is a randomized, double-blind, placebo-controlled trial conducted in the United States
Funding supports development of first-in-class pan-ROCK inhibitor ROC-101 through Phase 2a clinical testing
The inspection concluded with zero form 483 observations
Wegovy achieved significant weight loss with one in three study participants losing 20% or more body weight
IND application for EB-003 expected in early 2026
Pete Pharma will leverage FABRX’s extensive foundation of scientific validation to deliver a commercially viable, pharmacy-ready solution in the US
Subscribe To Our Newsletter & Stay Updated
